GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (NAS:RCEL) » Definitions » Asset Turnover

RCEL (AVITA Medical) Asset Turnover : 0.25 (As of Mar. 2025)


View and export this data going back to 2012. Start your Free Trial

What is AVITA Medical Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. AVITA Medical's Revenue for the three months ended in Mar. 2025 was $18.51 Mil. AVITA Medical's Total Assets for the quarter that ended in Mar. 2025 was $74.63 Mil. Therefore, AVITA Medical's Asset Turnover for the quarter that ended in Mar. 2025 was 0.25.

Asset Turnover is linked to ROE % through Du Pont Formula. AVITA Medical's annualized ROE % for the quarter that ended in Mar. 2025 was 153,988.89%. It is also linked to ROA % through Du Pont Formula. AVITA Medical's annualized ROA % for the quarter that ended in Mar. 2025 was -74.28%.


AVITA Medical Asset Turnover Historical Data

The historical data trend for AVITA Medical's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVITA Medical Asset Turnover Chart

AVITA Medical Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Dec22 Dec23 Dec24
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.28 0.31 0.48 0.67

AVITA Medical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.16 0.23 0.23 0.25

Competitive Comparison of AVITA Medical's Asset Turnover

For the Medical Devices subindustry, AVITA Medical's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVITA Medical's Asset Turnover Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Asset Turnover distribution charts can be found below:

* The bar in red indicates where AVITA Medical's Asset Turnover falls into.


;
;

AVITA Medical Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

AVITA Medical's Asset Turnover for the fiscal year that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=64.251/( (111.64+79.711)/ 2 )
=64.251/95.6755
=0.67

AVITA Medical's Asset Turnover for the quarter that ended in Mar. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=18.514/( (79.711+69.556)/ 2 )
=18.514/74.6335
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


AVITA Medical  (NAS:RCEL) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

AVITA Medical's annulized ROE % for the quarter that ended in Mar. 2025 is

ROE %**(Q: Mar. 2025 )
=Net Income/Total Stockholders Equity
=-55.436/-0.036
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-55.436 / 74.056)*(74.056 / 74.6335)*(74.6335/ -0.036)
=Net Margin %*Asset Turnover*Equity Multiplier
=-74.86 %*0.9923*-2073.1528
=ROA %*Equity Multiplier
=-74.28 %*-2073.1528
=153,988.89 %

Note: The Net Income data used here is four times the quarterly (Mar. 2025) net income data. The Revenue data used here is four times the quarterly (Mar. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

AVITA Medical's annulized ROA % for the quarter that ended in Mar. 2025 is

ROA %(Q: Mar. 2025 )
=Net Income/Total Assets
=-55.436/74.6335
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-55.436 / 74.056)*(74.056 / 74.6335)
=Net Margin %*Asset Turnover
=-74.86 %*0.9923
=-74.28 %

Note: The Net Income data used here is four times the quarterly (Mar. 2025) net income data. The Revenue data used here is four times the quarterly (Mar. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


AVITA Medical Asset Turnover Related Terms

Thank you for viewing the detailed overview of AVITA Medical's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


AVITA Medical Business Description

Traded in Other Exchanges
Address
28159 Avenue Stanford, Suite 220, Valencia, Santa Clarita, CA, USA, 91355
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
Executives
Robert Mcnamara director C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750
David D O'toole officer: CFO 1640 MARENGO STREET, LOS ANGELES CA 90033
Suzanne Crowe director C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
James Corbett director 2 GOODYEAR, IRVINE CA 92618
Jeremy Curnock Cook director TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101
Donna Shiroma officer: General Counsel C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Cary Guy Vance director 800 EAST MIDDLEFIELD RD, MOUNTAIN VIEW CA 94043
Michael S Perry director, officer: Chief Executive Officer C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Jan Stern Reed director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Michael Holder officer: Chief Financial Officer 6170 RESEARCH RD., STE 103, FRISCO TX 75034
Kathy M. Mcgee officer: Chief Operating Officer C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Sean Ekins officer: Sr. VP of Finance C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
David Mcintyre officer: Chief Financial Officer SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Erin Liberto officer: Chief Commercial Officer C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Andrew Quick officer: Chief Technology Officer C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 200, VALENCIA CA 91355